ADVERTISEMENT
Global health authorities are taking notice. The World Health Organization has recognized lenacapavir’s potential to expand prevention options worldwide, and regulatory bodies including the U.S. FDA and European regulators are moving toward wider approval and rollout.
Not a Cure — But a Transformative Tool
It’s important to emphasize that while lenacapavir offers extraordinary protection against HIV infection as PrEP, it is not a cure for HIV/AIDS. People living with HIV still rely on antiretroviral therapy to manage their condition. However, lenacapavir also shows promise in treatment settings — especially for individuals with multi‑drug‑resistant HIV — when used in combination with other medications.
Looking Ahead
As regulatory approvals and access programs expand — including efforts to make lenacapavir affordable in low‑ and middle‑income countries — the world may be on the cusp of a new era in HIV prevention. The potential to dramatically reduce new infections, particularly in high‑burden regions, has researchers and public health officials hopeful that adding lenacapavir to the prevention toolkit could bring the goal of
ADVERTISEMENT
